Salhofer-Polanyi S, Leutmezer F
Department of Neurology, Medical University of Vienna, Vienna, Austria.
Drugs Today (Barc). 2014 May;50(5):365-83. doi: 10.1358/dot.2014.50.5.2132741.
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, encompassing both neuroinflammatory as well as prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently licensed drugs could not satisfactorily halt this process. However, in the last years MS treatment has raised a stage of rapid progress. Several new drugs with significantly improved efficacy have entered the therapeutic field and several others are currently undergoing phase III clinical trials. In this review, we will summarize efficacy data as well as safety and tolerability issues of currently licensed drugs for relapsing-remitting MS and will give a short update on new drugs currently undergoing late-stage clinical trials.
多发性硬化症（MS）是一种中枢神经系统的自身免疫性疾病，兼具神经炎症和显著的神经退行性病变特征。随着时间推移，相当一部分MS患者会出现神经功能障碍，直到最近，获批药物仍无法令人满意地阻止这一进程。然而，在过去几年中，MS治疗取得了快速进展。几种疗效显著提高的新药已进入治疗领域，还有几种正在进行III期临床试验。在本综述中，我们将总结复发缓解型MS目前获批药物的疗效数据以及安全性和耐受性问题，并简要介绍目前正在进行后期临床试验的新药情况。
